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Abstract
The effect of insulin-induced hypoglycemia on cerebral glucose metabolism is largely
unknown. 13C MRS is a unique tool to study cerebral glucose metabolism, but the concurrent
requirement for [1-13C]glucose administration limits its use under hypoglycemic conditions. To
facilitate 13C MRS data analysis we designed separate [1-13C]glucose infusion protocols for
hyperinsulinemic euglycemic and hypoglycemic clamps in such a way that plasma isotopic
enrichment of glucose was stable and comparable under both glycemic conditions. 13C MR spectra
were acquired with optimized 13C MRS measurement techniques to obtain high quality 13C MR
spectra with these protocols.
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Introduction
Since glucose is of vital importance to preserve brain function, the human body takes great
effort in avoiding hypoglycemia to ensure constant glucose supply to the brain. In people with
type 1 diabetes, however, loss of endogenous insulin production and consequent insulin
injection therapy may lead to erratic glucose fluctuations and a considerable risk of
hypoglycemic episodes. Moreover, failure of glucose counterregulatory hormone or symptom
responses, normally elicited at blood glucose levels below ~3.8 mmol/L, may increase the risk
of deeper glucose reductions accompanied by declines in cognitive function (Cryer, Davis et
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al., 2003). Although the brain is thought to play a central role in the detection of hypoglycemia
and the initiation of counterregulatory responses, the effect of hypoglycemia on brain glucose
metabolism is largely unknown.
13C MR spectroscopy is a unique tool to study glucose metabolism in the brain non-invasively.
Because of the low natural abundance of the 13C isotope (1.1%) metabolic conversions can be
visualized after administering 13C-enriched compounds by infusion or oral intake and then
monitoring the passage of the isotope through different metabolic pathways. Since more than
two decades 13C-labeled glucose has been successfully applied for in vivo studies of cerebral
glucose uptake and metabolic conversions, starting first in animals (Rothman, Behar et al.,
1985) and later also in humans (Beckmann, Turkalj et al., 1991). Since then, studies perfomed
with 13C MRS or 1H-observe 13C-edited MRS in combination with 13C-labeled compounds
have provided novel information on important neurochemical processes (e.g. see de Graaf,
Mason et al., 2003, Gruetter, Adriany et al., 2003, Garcia-Espinosa, Rodrigues et al., 2004).
To ensure optimal detection 13C in the brain, experiments using 13C-glucose for isotopic
enrichment have been commonly employed after administration of high doses of the label and
under hyperglycemic conditions. As the blood-brain barrier usually limits the capacity for
glucose uptake in the brain, these studies have greatly advanced our understanding of in vivo
glucose metabolism by the intact human brain. However, direct MRS assessment of brain
metabolism under hypoglycemic conditions is complicated. The effect of hypoglycemia on
cerebral glucose metabolism has been studied by 13C MR spectroscopy in brain slices
(Bachelard, Badar-Goffer et al., 1993) and recently in animals (Jiang, Herzog et al.,
2009). 13C MRS of the human brain was applied during hypoglycemia to monitor glycogen
utilization and formation (Oz, Kumar et al., 2009) and monocarboxylic acid transport (Mason,
Petersen et al., 2006), but none of these studies used simultaneous infusion of 13C labeled
glucose to follow its metabolism.
In this study, we tested the feasibility to study human brain glucose metabolism directly
by 13C MRS at 3 Tesla under euglycemic and hypoglycemic conditions after 1) improving
SNR for reliable measurements at lower plasma 13C enrichment levels and 2) by designing
a 13C-enriched glucose infusion protocol that resulted in plasma glucose 13C enrichment of
sufficient magnitude to perform data analysis of 13C signals from glucose derived metabolites.
We specifically aimed for stable and broadly similar plasma glucose 13C enrichment levels
under both glycemic conditions, so as to facilitate 13C MRS dynamic data analyses and making
the results of both experiments directly comparable. Previously we reported on the technical
adjustments to the MR coil design (Klomp, Renema et al., 2006) and the pulse sequence
(Klomp, Kentgens et al., 2008). Here we present the infusion protocols,
Materials and methods
Subjects
Written informed consent was obtained from 7 healthy volunteers (female, mean age±sd, 21.8
±2.0 years) to participate in one of the protocols of the study. The study was approved by the
institutional review board of the Radboud University Nijmegen Medical Centre. All subjects
came to the Magnetic Resonance facility at 8.15 in the morning in fasting condition. The
brachial artery of the non-dominant arm was cannulated (Angiocath 20-gauge, Beckton
Dickinson, Sandy, UT) under local anaesthesia (Xylocaine 2%) for frequent blood sampling.
An intravenous catheter was inserted into an antecubital vein of the contralateral arm for
infusion of insulin (Actrapid, Novo Nordisk, Bagsvaerd, Denmark) and [1-13C]glucose 20%
(w/w) (Campro, Veenendaal, The Netherlands) at the required enrichtment percentage. After
an equilibration period of 30 minutes, subjects were positioned supine on the MR scanner bed
van de Ven et al. Page 2













with the head inside the dedicated RF coil, and then placed headfirst inside the bore of the
magnet.
Glucose infusion protocols
All volunteers were subjected to one of two different hyperinsulinemic glucose clamp protocols
which included a eu- and a hypoglycemic period, as a modification to a previously described
method (de Galan, Tack et al., 2002). All clamps were initiated 30 minutes after the subject
was placed into the scanner and baseline MRS data had been acquired.
Protocol 1 (n=4)—This protocol consisted of a hyperinsulinemic euglycemic-hypoglycemic
clamp in which plasma glucose was sequentially clamped at 5.0 mmol/L and 3.0 mmol/L for
45 minutes each. Insulin was infused at a rate of 60 mU.m−2.min−1 during the euglycemic
phase, but increased to 120 mU.m−2.min−1 upon initiation of the hypoglycemic phase. A bolus
of 6 g [1-13C]glucose with a fractional enrichment of 100% was infused over the first 10
minutes of the clamp, followed by variable infusion of 30% enriched [1-13C]glucose during
euglycemia. During hypoglycemia 100% enriched [1-13C]glucose was used in one volunteer
to maximize SNR in this phase. Later experiments were performed with 30% enriched
[1-13C]glucose during hypoglycemia. The [1-13C]glucose infusion rate was adjusted by arterial
plasma glucose levels measured at 5-minute intervals to maintain plasma glucose at the target
level, while part of the sampled blood was stored for later determination of plasma glucose
isotopic enrichment.
Protocol 2 (n=3)—This protocol consisted of hyperinsulinemic euglycemic and
hypoglycemic clamp studies performed in random order, separated by four weeks. During both
clamps, the insulin infusion rate was set at 120 mU.m−2.min−1 for 10 minutes and then at 60
mU.m−2.min−1 for the remainder of the experiments. Except for the similar bolus of 100%
labeled [1-13C]glucose at the beginning of each clamp, [1-13C]glucose with 40% fractional
enrichment was used for the euglycemic clamp and [1-13C]glucose with 50% fractional
enrichment was used for the hypoglycemic clamp, aiming at similar plasma glucose 13C
enrichment levels.
MR Spectroscopy
All studies were performed on a 3T MR system (Magnetom Trio, Siemens, Erlangen,
Germany). In protocol 1 a combination of a 1H circularly polarized and a 13C linearly polarized
surface coil (Adriany and Gruetter, 1997) was used for the first volunteer. Acquisition was
performed with a basic 13C-FID sequence with outer-volume suppression (OVS). The other
experiments were performed with a new coil design consisting of a 1H volume coil and a
circularly polarized 13C surface coil (Klomp, Renema et al., 2006), while the acquisition
sequence was optimized from a 13C-FID with OVS to a sequence with 1H to 13C cross-
polarization to increase SNR. In protocol 2 the optimized coil-setup was used together with a
more advanced DEPT sequence for 1H to 13C polarization transfer combined with 1H-ISIS
localization (Klomp, Kentgens et al., 2008). Adiabatic 13C pulses were used in all sequences
to ensure homogeneous excitation using the 13C coils, as well as WALTZ-16 proton decoupling
(Shaka, Keeler et al., 1983) to simplify the spectra and enhance SNR. In all experiments one
spectrum consisted of 72 repetitions of 2 seconds allowing a time resolution of 2.5 minutes.
Eight reference spectra were obtained before the start of [1-13C]glucose infusion, to correct
dynamic spectra for natural abundance 13C signal and residual lipid signals. In the unlocalized
experiments all signal from the occipital brain tissue was acquired, while in the localized ISIS-
DEPT experiments a voxel of ~125 ml was placed in this region.
van de Ven et al. Page 3














13C MRS data processing—The reference spectra were averaged and subtracted from the
dynamic spectra to remove all natural abundance 13C signals including those originating from
lipids. To enhance SNR the corrected spectra were added in running averages of 15 min. The
spectra were fitted in jMRUI (Naressi, Couturier et al., 2001) with the AMARES algorithm
(Vanhamme, van den Boogaart A. et al., 1997). The SNR of the spectra was defined as the
ratio of the highest signal intensity (Glutamate-C4) in a running average spectrum at t=100
min divided by the standard deviation (SD) of the noise in the region 100–120 ppm (SNR=
Glutamate-C4/SDnoise).
Blood samples—Arterial blood was sampled for all measurements. Plasma glucose was
measured in duplicate by the glucose oxidation method (Beckmann Glucose Analyzer II,
Fullerton, CA). All other blood samples were immediately stored on ice for 30 minutes,
followed by centrifugation for 15 minutes at 3000 rpm. The supernatant was stored at −80°C
to obtain plasma glucose isotopic 13C enrichment at a different day using high resolution 1H-
NMR at 500 MHz.
All data are expressed as means ± standard deviation (sd).
Results
In all experiments, plasma glucose levels peaked 10–15 minutes after initiation of the clamps
at 7–8 mmol/L. In protocol 1 glucose levels stabilized first at 5.5±0.2 mmol/L, followed by a
hypoglycemic phase in which glucose levels stabilized at 2.7±0.2 (figure 1a). In protocol 2
glucose values were stable at 5.2±0.1 and 2.9±0.1 mmol/L for the euglycemic and
hypoglycemic phase, respectively (figure 1b).
Plasma glucose 13C enrichment also peaked early during the clamps (figure 1c/d), and
subsequently remained stable during the euglycemic phases of all protocols. During
hypoglycemia, fractional enrichment increased steeply when 100% enriched [1-13C]glucose
was infused and decreased when the 30% enriched [1-13C]glucose was continued, despite
doubling of the insulin infusion rate (protocol 1, figure 1c). The use of different label
percentages for the separate euglycemic and hypoglycemic clamp experiments (protocol 2,
figure 1d) resulted in stable and comparable plasma isotopic enrichment of [1-13C]glucose
during euglycemia (36.0±0.6%) and hypoglycemia (34.6±1.4%).
During all experiments 13C MR spectra were acquired continuously, clearly showing signals
of glucose and several of its downstream metabolites. The increase in signals commonly
observed in time-series of spectra obtained under hyperglycemic conditions were also observed
under euglycemic and hypoglycemic conditions (figure 2a). The SNR of the spectra was
calculated as 41.3±7.4 during euglycemia and 33.8±10.3 during hypoglycemia. The course of
label incorporation into various glucose metabolic compounds was evaluated from these
spectra. The data showed steep increases of label incorporation into glutamate-C4 during the
first 30 minutes followed by a more gradual increase for the remainder of the experiments. The
experiment in which 100% [1-13C]glucose was used during the hypoglycemic phase of the
clamp showed ongoing label incorporation of all metabolites during hypoglycemia, indicating
continuing glucose uptake and metabolism (figure 2b).
Discussion
This study presents a [1-13C]glucose infusion protocol that together with enhanced 13C MRS
sensitivity enables the use of 13C MRS at 3T for investigating brain glucose metabolism under
in vivo euglycemic and hypoglycemic conditions. To do so, we optimized MRS hardware and
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sequences and tested various infusion protocols. Our final protocol, consisting of euglycemic
and hypoglycemic clamps performed on separate days and with the use of different label
percentages for [1-13C]glucose, resulted in comparable and stable plasma 13C enrichment of
sufficient magnitude over time, while maintaining stable plasma glucose values. The spectra
were of good quality for the assessment of 13C-labeled derivates of glucose. [KCC1]
Several factors potentially limit the use of 13C MRS under eu- and hypoglycemic conditions
for dynamic studies of glucose metabolism in the brain. The low sensitivity of 13C MRS
requires infusion of large amounts of 13C-enriched glucose, whereas activated glucose
counterregulation increases endogenous glucose production during hypoglycemia, thus
reducing the requirement of exogenous glucose and therefore of [1-13C]glucose. It was not
feasible to perform eu- and hypoglycemic clamps consecutively in one experiment for a number
of reasons. First, the ‘history’ of 13C label at the start of the hypoglycemic period complicates
the already challenging data analysis. Secondly, such experiments would take considerably
longer for plasma isotopic enrichment to stabilize during hypoglycemia, if at all possible
considering subject discomfort. These issues were overcome by performing the clamps on
separate occasions, by using a bolus of 100% enriched [1-13C]glucose to rapidly obtain target
plasma enrichment levels, and by using higher [1-13C]glucose label percentages for
hypoglycemic experiments. Glucose 13C enrichment values thus obtained were stable and of
equivalent magnitude, which makes current results directly comparable and may aid in future
data analysis. However, this approach assumes little intra-individual variation in basal
neurometabolic rate over time, which may not always be the case. Future studies will therefore
require careful randomization.
Performing 13C MRS of the brain under euglycemic conditions may prove valuable to study
in vivo brain glucose metabolism in situations where the assumption of limited glucose
transport over the blood-brain barrier is not valid, such as in brain tumors. The successful
application of 13C MRS of the brain under hypoglycemic conditions creates new opportunities
to investigate the effect of hypoglycemia on cerebral glucose metabolism beyond the blood-
brain barrier directly. The use of [1-13C]glucose at 40–50% isotopic enrichment resulted in
sufficient SNR for volumes of ~125 ml, at costs that are much lower than would have been the
case with higher isotopic enrichment or with the use of [1,6-13C]glucose (de Graaf, Mason et
al., 2003). Potentially, however, the use of higher isotopic enrichment would enable
measurements in smaller voxels, so that information of specific parts of the brain, for example
in the glucose sensing region of the hypothalamus, can be obtained.
In conclusion, we developed a 13C glucose infusion protocol that enabled high quality 13C
MRS under both euglycemic and hypoglycemic conditions. Future work will need to address
the dynamics in the level of several metabolites by modeling.
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Plasma glucose levels of protocol 1 (panel a) and protocol 2 (panel b), and corresponding
fractional 13C isotopic enrichment of plasma glucose (panels c and d). Data from 1 subject
receiving 100% enriched [1-13C]glucose during hypoglycemia (gray) is separated from the
results of the other 3 subjects who received 30% enriched [1-13C]glucose (black) (panel c).
All data are expressed as mean ± sd.
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a) Representative MR spectra of one subject under hypoglycemic condition (protocol 2),
averaged over 20 minutes. b) Curves of Glutamate-C4 signal integral in protocol 2 as a function
of time under hypoglycemia (light gray), under euglycemia (dark gray) and for protocol 1,
where a euglycemic period with 30% enriched [1-13C]glucose infusion was followed by a
hypoglycemic period with infusion of 100% enriched [1-13C]glucose (black).
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